114 related articles for article (PubMed ID: 31898661)
1. Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression.
Li L; Nan F; Guo Q; Guan D; Zhou C
J Cancer Res Ther; 2019; 15(6):1282-1287. PubMed ID: 31898661
[TBL] [Abstract][Full Text] [Related]
2. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.
Kathawala RJ; Wei L; Anreddy N; Chen K; Patel A; Alqahtani S; Zhang YK; Wang YJ; Sodani K; Kaddoumi A; Ashby CR; Chen ZS
Oncotarget; 2015 Jan; 6(1):510-21. PubMed ID: 25402202
[TBL] [Abstract][Full Text] [Related]
3. The Pyrazolo[3,4-
Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
[TBL] [Abstract][Full Text] [Related]
4. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
[TBL] [Abstract][Full Text] [Related]
5. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Ferguson BD; Liu R; Rolle CE; Tan YH; Krasnoperov V; Kanteti R; Tretiakova MS; Cervantes GM; Hasina R; Hseu RD; Iafrate AJ; Karrison T; Ferguson MK; Husain AN; Faoro L; Vokes EE; Gill PS; Salgia R
PLoS One; 2013; 8(7):e67668. PubMed ID: 23844053
[TBL] [Abstract][Full Text] [Related]
6. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
[TBL] [Abstract][Full Text] [Related]
7. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Li X; Choi WW; Yan R; Yu H; Krasnoperov V; Kumar SR; Schuckman A; Klumpp DJ; Pan CX; Quinn D; Gill IS; Gill PS; Liu R
PLoS One; 2014; 9(8):e105326. PubMed ID: 25148033
[TBL] [Abstract][Full Text] [Related]
8. EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Becerikli M; Merwart B; Lam MC; Suppelna P; Rittig A; Mirmohammedsadegh A; Stricker I; Theiss C; Singer BB; Jacobsen F; Steinstraesser L
Int J Cancer; 2015 Apr; 136(8):1781-91. PubMed ID: 25274141
[TBL] [Abstract][Full Text] [Related]
9. EphB4/ TNFR2/ERK/MAPK signaling pathway comprises a signaling axis to mediate the positive effect of TNF-α on osteogenic differentiation.
Zhang Y; Yang C; Ge S; Wang L; Zhang J; Yang P
BMC Mol Cell Biol; 2020 Apr; 21(1):29. PubMed ID: 32299362
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.
Lennon S; Oweida A; Milner D; Phan AV; Bhatia S; Van Court B; Darragh L; Mueller AC; Raben D; Martínez-Torrecuadrada JL; Pitts TM; Somerset H; Jordan KR; Hansen KC; Williams J; Messersmith WA; Schulick RD; Owens P; Goodman KA; Karam SD
Clin Cancer Res; 2019 Jun; 25(11):3352-3365. PubMed ID: 30944125
[TBL] [Abstract][Full Text] [Related]
11. EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Li L; Xu N; Zhang JF; Xu LL; Zhou X; Huang BT; Li YL; Liu XL
Int J Med Sci; 2016; 13(5):365-73. PubMed ID: 27226777
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
Guijarro-Muñoz I; Sánchez A; Martínez-Martínez E; García JM; Salas C; Provencio M; Alvarez-Vallina L; Sanz L
Med Oncol; 2013; 30(2):572. PubMed ID: 23579861
[TBL] [Abstract][Full Text] [Related]
13. EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Xuqing W; Lei C; Zhengfa M; Shengchun D; Xin F; Jianguo Q; Jianxin Z
Tumour Biol; 2012 Oct; 33(5):1419-27. PubMed ID: 22528941
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
[TBL] [Abstract][Full Text] [Related]
15. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
16. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
Zhao WH; Huang BT; Zhang JY; Zeng QC
Leuk Res; 2017 Dec; 63():28-33. PubMed ID: 29096333
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
[TBL] [Abstract][Full Text] [Related]
18. EphB4 as a therapeutic target in mesothelioma.
Liu R; Ferguson BD; Zhou Y; Naga K; Salgia R; Gill PS; Krasnoperov V
BMC Cancer; 2013 May; 13():269. PubMed ID: 23721559
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
[No Abstract] [Full Text] [Related]
20. EphB4 expression and biological significance in prostate cancer.
Xia G; Kumar SR; Masood R; Zhu S; Reddy R; Krasnoperov V; Quinn DI; Henshall SM; Sutherland RL; Pinski JK; Daneshmand S; Buscarini M; Stein JP; Zhong C; Broek D; Roy-Burman P; Gill PS
Cancer Res; 2005 Jun; 65(11):4623-32. PubMed ID: 15930280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
